rs,
mited (2) National Stock Exchange of India Limited Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 Listing Department Exchange Plaza, 5th floor, Plot no. C/1, G Bloc
6%
iness drive Q3FY22 performance CLICK TO EDIT MASTER TITLE STYLE Overall Revenue Overall EBITDA 6% (Q3 YoY Growth in INR Terms) Sustained traction across branded & generic markets; modest contr
22.7%
traction across branded & generic markets; modest contribution of covid products EBITDA Margin 22.7% Continued strong margin trajectory One India SAGA 13% (Q3 YoY Growth in INR Terms) Sustaine
13%
ion of covid products EBITDA Margin 22.7% Continued strong margin trajectory One India SAGA 13% (Q3 YoY Growth in INR Terms) Sustained momentum across core therapies and traction in flagship
4%
NR Terms) Sustained momentum across core therapies and traction in flagship brands Overall SAGA 4% SA Private Market 16% (Q3 YoY growth in $ Terms) (Q3 YoY growth in ZAR Terms) North America I
16%
mentum across core therapies and traction in flagship brands Overall SAGA 4% SA Private Market 16% (Q3 YoY growth in $ Terms) (Q3 YoY growth in ZAR Terms) North America International Markets & A
7%
ust momentum in core business; strong traction in respiratory portfolio $150 Mn Q3FY22 Revenues 7% International 2% API 27% (Q3 YoY growth in $ Terms) (Q3 YoY growth in $ Terms) (Q3 YoY growt
2%
e business; strong traction in respiratory portfolio $150 Mn Q3FY22 Revenues 7% International 2% API 27% (Q3 YoY growth in $ Terms) (Q3 YoY growth in $ Terms) (Q3 YoY growth in $ Terms) Stro
27%
s; strong traction in respiratory portfolio $150 Mn Q3FY22 Revenues 7% International 2% API 27% (Q3 YoY growth in $ Terms) (Q3 YoY growth in $ Terms) (Q3 YoY growth in $ Terms) Strong capital
15.9%
arkets US Generics ✓ Approval for Lanreotide injection 505 (b)(2) ✓ Albuterol total market share1 15.9%|Arformoterol total market share1 26.8% One India ✓ Launched Spirofy®; India's first pneumotach ba
26.8%
reotide injection 505 (b)(2) ✓ Albuterol total market share1 15.9%|Arformoterol total market share1 26.8% One India ✓ Launched Spirofy®; India's first pneumotach based portable wireless Spirometer for
INR 5,479
ing 21st December 2021 Financial Performance – Q3FY22 CLICK TO EDIT MASTER TITLE STYLE Revenues INR 5,479 Cr 6% YoY EBITDA INR 1,243 Cr │ 22.7% 3% YoY Q3 FY22 (Consolidated) Revenue1 Break-up Tot